Singapore Advanced Therapy Manufacturing Market Forecast to 2035 by Therapy Type, Scale, Manufacturer, Application, and End User | 27.37% CAGR Unlocks USD 1.56 Billion Opportunity
Dublin, Oct. 01, 2026 (GLOBE NEWSWIRE) -- "Singapore Advanced Therapy Manufacturing Market by Therapy Type, Scale of Operation, Type of Manufacturer, Application and End User - Trends and Growth Forecast, Till 2035" has been added to ResearchAndMarkets.com's offering.
The Singapore advanced therapy manufacturing market is estimated at USD 177 million in the current year and is projected to exceed USD 1,562 million by 2035. The market is expected to expand at a compound annual growth rate of 27.37% during the forecast period.
Singapore has developed into a strategic hub for cell therapies, gene therapies, tissue-engineered products, antibody-drug conjugates and other next-generation biologics. Its growth is supported by national research platforms, regulatory alignment, government incentives and sustained investment in bioprocessing, viral vector production, fill-finish operations and cold-chain infrastructure.
Market Growth and Investment Trends
The Singapore Economic Development Board, the Agency for Science, Technology and Research and the Health Sciences Authority are helping accelerate advanced therapy manufacturing through facility co-funding, workforce development and regulatory pathways aligned with the US FDA and EU EMA.
Major investments include AstraZeneca's USD 1.5 billion antibody-drug conjugate facility, its first end-to-end ADC manufacturing site globally, and WuXi Biologics' USD 2 billion biomanufacturing facility in Tuas. SCG Cell Therapy has also established an EDB-backed cGMP cell therapy manufacturing and R&D center supporting clinical and commercial development.
The Nucleic Acid Therapeutics Initiative mRNA Biofoundry further strengthens Singapore's position in next-generation therapeutic manufacturing. As the first facility in Asia capable of producing gram-scale mRNA therapeutics, it expands national capabilities across nucleic-acid medicines and vaccines.
Key Singapore Advanced Therapy Manufacturing Market Drivers
Market Challenges
High operating costs, limited land availability and the capital intensity of automated facilities remain important barriers to market entry. Singapore also faces a shortage of specialized bioprocessing talent, although training programmes led by A*STAR's Bioprocessing Technology Institute are helping address workforce requirements.
The country's small domestic patient population limits local commercial volumes for autologous therapies, making export-oriented and CDMO-driven business models essential for scale. Manufacturers must also manage competition from lower-cost Asian production centers, differing regulations across ASEAN countries and complex last-mile distribution requirements.
Commercial Opportunities and Key Insights
Market Segmentation and Outlook
The Singapore advanced therapy manufacturing market is analyzed by therapy type, scale of operation, manufacturer type, application and end user.
Cell therapies currently represent the largest revenue share, supported by established iPSC and CAR-T-adjacent manufacturing capabilities. Gene therapies are expected to register the fastest CAGR through 2035 as viral-vector and nucleic-acid capacity expands.
CDMOs are gaining market share as biotechnology companies prioritize flexible, GMP-compliant outsourced production. Oncology remains the leading application segment, supported by strong global development activity in cell therapies and antibody-drug conjugates. Rare and genetic disorders are expected to record rapid growth as more gene therapies progress toward approval and commercialization.
Recent Market Activity
Companies Active in the Market
Notable participants and ecosystem partners include A*STAR Bioprocessing Technology Institute, Amgen, AstraZeneca, Esco Aster, GSK, Hilleman Laboratories, Lonza, SCG Cell Therapy, Thermo Fisher Scientific and WuXi Biologics.
Research Coverage
The report provides market sizing and forecasts, manufacturer benchmarking, company profiles, partnership analysis and an assessment of Singapore's regulatory and policy environment. It evaluates facility investments, ownership models, modality portfolios, export orientation and commercialization constraints. The research also examines how outsourcing, workforce availability, cold-chain capacity and nucleic-acid manufacturing will influence market growth through 2035.
Reasons to Buy the Report
Additional Benefits
Key Topics Covered:
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Research Assumptions
2.2. Database Building
2.2.1. Data Collection
2.2.2. Data Validation
2.2.3. Data Analysis
2.3. Project Methodology
2.3.1. Secondary Research
2.3.1.1. Annual Reports
2.3.1.2. Academic Research Papers
2.3.1.3. Company Websites
2.3.1.4. Investor Presentations
2.3.1.5. Regulatory Filings
2.3.1.6. White Papers
2.3.1.7. Industry Publications
2.3.1.8. Conferences and Seminars
2.3.1.9. Government Portals
2.3.1.10. Media and Press Releases
2.3.1.11. Newsletters
2.3.1.12. Industry Databases
2.3.1.13. Roots Proprietary Databases
2.3.1.14. Paid Databases and Sources
2.3.1.15. Social Media Portals
2.3.1.16. Other Secondary Sources
2.3.2. Primary Research
2.3.2.1. Introduction
2.3.2.2. Types
2.3.2.2.1. Qualitative
2.3.2.2.2. Quantitative
2.3.2.3. Advantages
2.3.2.4. Techniques
2.3.2.4.1. Interviews
2.3.2.4.2. Surveys
2.3.2.4.3. Focus Groups
2.3.2.4.4. Observational Research
2.3.2.4.5. Social Media Interactions
2.3.2.5. Stakeholders
2.3.2.5.1. Company Executives (CXOs)
2.3.2.5.2. Board of Directors
2.3.2.5.3. Company Presidents and Vice Presidents
2.3.2.5.4. Key Opinion Leaders
2.3.2.5.5. Research and Development Heads
2.3.2.5.6. Technical Experts
2.3.2.5.7. Subject Matter Experts
2.3.2.5.8. Scientists
2.3.2.5.9. Doctors and Other Healthcare Providers
2.3.2.6. Ethics and Integrity
2.3.2.6.1. Research Ethics
2.3.2.6.2. Data Integrity
2.3.3. Analytical Tools and Databases
3. MARKET DYNAMICS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach
3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)
3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis
3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation
3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Time Period
4.1.1. Historical Trends
4.1.2. Current and Forecasted Estimates
4.2. Currency Coverage
4.2.1. Overview of Major Currencies Affecting the Market
4.2.2. Impact of Currency Fluctuations on the Industry
4.3. Foreign Exchange Impact
4.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.3.2. Strategies for Mitigating Foreign Exchange Risk
4.4. Recession
4.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
4.5. Inflation
4.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.5.2. Potential Impact of Inflation on the Market Evolution
4.6. Interest Rates
4.6.1. Overview of Interest Rates and Their Impact on the Market
4.6.2. Strategies for Managing Interest Rate Risk
4.7. Commodity Flow Analysis
4.7.1. Type of Commodity
4.7.2. Origins and Destinations
4.7.3. Values and Weights
4.7.4. Modes of Transportation
4.8. Global Trade Dynamics
4.8.1. Import Scenario
4.8.2. Export Scenario
4.9. War Impact Analysis
4.9.1. Russian-Ukraine War
4.9.2. Israel-Hamas War
4.10. COVID Impact / Related Factors
4.10.1. Global Economic Impact
4.10.2. Industry-specific Impact
4.10.3. Government Response and Stimulus Measures
4.10.4. Future Outlook and Adaptation Strategies
4.11. Other Indicators
4.11.1. Fiscal Policy
4.11.2. Consumer Spending
4.11.3. Gross Domestic Product (GDP)
4.11.4. Employment
4.11.5. Taxes
4.11.6. R&D Innovation
4.11.7. Stock Market Performance
4.11.8. Supply Chain
4.11.9. Cross-Border Dynamics
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Overview of Singapore Advanced Therapy Manufacturing
6.1.1. Key Characteristics of Singapore Advanced Therapy Manufacturing
6.1.2. Key Applications of Singapore Advanced Therapy Manufacturing
6.1.3. Challenges Associated with Singapore Advanced Therapy Manufacturing
6.2. Future Perspective
7. REGULATORY SCENARIO
8. COMPREHENSIVE DATABASE OF LEADING PLAYERS
9. COMPETITIVE LANDSCAPE
9.1. Singapore Advanced Therapy Manufacturing: Overall Market Landscape
9.1.1. Analysis by Year of Establishment
9.1.2. Analysis by Company Size
9.1.3. Analysis by Location of Headquarters
9.1.4. Analysis by Therapy Type
9.1.5. Analysis by Scale of Operation Type
9.1.6. Analysis by Manufacturer Type
9.1.7. Analysis by Application
9.1.8. Analysis by End User
10. COMPANY COMPETITIVENESS ANALYSIS
10.1. Assumptions and Key Parameters
10.2. Methodology
10.3. Overview of Peer Groups Based in Singapore
11. COMPANY PROFILES
11.1. A*STAR Bioprocessing Technology Institute (Research and Technology-Transfer Partner)
11.1.1. Company Overview
11.1.2. Company Mission
11.1.3. Company Footprint
11.1.4. Management Team
11.1.5. Contact Details
11.1.6. Financial Performance
11.1.7. Operating Business Segments
11.1.8. Product Portfolio
11.1.9. MOAT Analysis
11.1.10. Recent Developments and Future Outlook
11.2. Amgen
11.3. AstraZeneca
11.4. Esco Aster
11.5. GSK
11.6. Hilleman Laboratories
11.7. Lonza
11.8. SCG Cell Therapy
11.9. Thermo Fisher Scientific
11.10. WuXi Biologics
12. RECENT DEVELOPMENTS
12.1. Recent Funding
12.2. Recent Partnerships
12.3. Other Recent Initiatives
13. SINGAPORE ADVANCED THERAPY MANUFACTURING MARKET
13.1. Key Assumptions and Methodology
13.2. Revenue Shift Analysis
13.3. Market Movement Analysis
13.4. Penetration-Growth (P-G) Matrix
13.5. Trends Disrupting the Market
13.6. Demand Side Trends
13.7. Supply Side Trends
13.8. Singapore Advanced Therapy Manufacturing Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
13.9. Multivariate Scenario Analysis
13.9.1. Conservative Scenario
13.9.2. Optimistic Scenario
13.10. Investment Feasibility Index
13.11. Key Market Segmentations
13.12. Data Triangulation and Validation
13.12.1. Secondary Sources
13.12.2. Primary Sources
13.12.3. Statistical Modeling
14. MARKET OPPORTUNITIES BASED ON TYPE OF THERAPY
14.1. Singapore Advanced Therapy Manufacturing Market for Cell Therapy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.2. Singapore Advanced Therapy Manufacturing Market for Gene Therapy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.3. Singapore Advanced Therapy Manufacturing Market for Tissue-Engineered Products: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
14.4. Antibody-Drug Conjugates (ADCs) and Other Advanced Biologics
15. MARKET OPPORTUNITIES BASED ON TYPE OF SCALE OF OPERATION
15.1. Singapore Advanced Therapy Manufacturing Market for Preclinical / Clinical: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
15.2. Singapore Advanced Therapy Manufacturing Market for Commercial: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16. MARKET OPPORTUNITIES BASED ON TYPE OF MANUFACTURER
16.1. Singapore Advanced Therapy Manufacturing Market for In-House Manufacturers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
16.2. Singapore Advanced Therapy Manufacturing Market for Contract Development and Manufacturing Organizations (CDMOs): Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17. MARKET OPPORTUNITIES BASED ON TYPE OF APPLICATION
17.1. Singapore Advanced Therapy Manufacturing Market for Oncology: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.2. Singapore Advanced Therapy Manufacturing Market for Rare and Genetic Disorders: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.3. Singapore Advanced Therapy Manufacturing Market for Infectious Diseases: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
17.4. Singapore Advanced Therapy Manufacturing Market for Other Indications: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18. MARKET OPPORTUNITIES BASED ON TYPE OF END USER
18.1. Singapore Advanced Therapy Manufacturing Market in Biopharmaceutical Companies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
18.2. Singapore Advanced Therapy Manufacturing Market in Hospitals and Academic Medical Centers: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
19. KEY WINNING STRATEGIES
20. STRATEGIC RECOMMENDATIONS
21. INSIGHTS FROM PRIMARY RESEARCH
22. REPORT CONCLUSION
23. TABULATED DATA
24. LIST OF COMPANIES AND ORGANIZATIONS
25. SUBSCRIPTION SERVICES
26. AUTHOR DETAILS
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/q8iq0y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.